PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), announced plans to file a Schedule 13D disclosing a 5.09% ownership stake in Alaunos Therapeutics (TCRT). The stake represents 83,500 shares of the clinical-stage oncology-focused cell therapy company, based on Alaunos' 1,639,521 outstanding shares as of May 5, 2025.
PMGC Capital believes Alaunos is undervalued and sees significant potential for shareholder value creation. Alaunos is currently exploring strategic alternatives, including mergers, acquisitions, asset sales, and strategic partnerships. PMGC Capital plans to engage with Alaunos' management to explore strategic opportunities, particularly in fintech and cryptocurrency sectors.
PMGC Capital LLC, una controllata di PMGC Holdings Inc. (ELAB), ha annunciato l'intenzione di presentare un modulo Schedule 13D per dichiarare una quota di partecipazione del 5,09% in Alaunos Therapeutics (TCRT). Questa quota corrisponde a 83.500 azioni della società biotecnologica focalizzata sulla terapia cellulare oncologica in fase clinica, basandosi sulle 1.639.521 azioni in circolazione di Alaunos al 5 maggio 2025.
PMGC Capital ritiene che Alaunos sia sottovalutata e intraveda un significativo potenziale di creazione di valore per gli azionisti. Alaunos sta attualmente valutando alternative strategiche, tra cui fusioni, acquisizioni, cessioni di asset e partnership strategiche. PMGC Capital intende collaborare con la direzione di Alaunos per esplorare opportunità strategiche, in particolare nei settori fintech e delle criptovalute.
PMGC Capital LLC, una subsidiaria de PMGC Holdings Inc. (ELAB), anunció planes para presentar un Schedule 13D revelando una participación accionaria del 5,09% en Alaunos Therapeutics (TCRT). Esta participación representa 83,500 acciones de la empresa de terapia celular enfocada en oncología en etapa clínica, basada en las 1,639,521 acciones en circulación de Alaunos al 5 de mayo de 2025.
PMGC Capital considera que Alaunos está infravalorada y ve un potencial significativo para la creación de valor para los accionistas. Actualmente, Alaunos está explorando alternativas estratégicas, incluyendo fusiones, adquisiciones, ventas de activos y asociaciones estratégicas. PMGC Capital planea involucrarse con la dirección de Alaunos para explorar oportunidades estratégicas, especialmente en los sectores fintech y de criptomonedas.
PMGC Capital LLC는 PMGC Holdings Inc. (ELAB)의 자회사로서 Alaunos Therapeutics (TCRT)의 5.09% 지분을 공개하는 Schedule 13D를 제출할 계획을 발표했습니다. 이 지분은 2025년 5월 5일 기준 Alaunos의 총 1,639,521주 중 83,500주에 해당하며, 임상 단계의 종양학 중심 세포 치료 회사입니다.
PMGC Capital은 Alaunos가 저평가되어 있다고 보고 있으며 주주 가치 창출에 상당한 잠재력이 있다고 판단합니다. Alaunos는 현재 합병, 인수, 자산 매각 및 전략적 파트너십 등 전략적 대안을 모색 중입니다. PMGC Capital은 특히 핀테크 및 암호화폐 분야에서 전략적 기회를 탐색하기 위해 Alaunos 경영진과 협력할 계획입니다.
PMGC Capital LLC, une filiale de PMGC Holdings Inc. (ELAB), a annoncé son intention de déposer un Schedule 13D révélant une participation de 5,09% dans Alaunos Therapeutics (TCRT). Cette participation représente 83 500 actions de cette société de thérapie cellulaire oncologique en phase clinique, sur la base des 1 639 521 actions en circulation d'Alaunos au 5 mai 2025.
PMGC Capital estime qu'Alaunos est sous-évaluée et perçoit un potentiel important de création de valeur pour les actionnaires. Alaunos explore actuellement des alternatives stratégiques, notamment des fusions, acquisitions, ventes d'actifs et partenariats stratégiques. PMGC Capital prévoit d'engager un dialogue avec la direction d'Alaunos pour explorer des opportunités stratégiques, notamment dans les secteurs de la fintech et des cryptomonnaies.
PMGC Capital LLC, eine Tochtergesellschaft von PMGC Holdings Inc. (ELAB), kündigte Pläne an, ein Schedule 13D einzureichen, in dem ein 5,09%iger Eigentumsanteil an Alaunos Therapeutics (TCRT) offengelegt wird. Dieser Anteil entspricht 83.500 Aktien des klinisch orientierten Onkologie-Zelltherapieunternehmens, basierend auf 1.639.521 ausstehenden Aktien von Alaunos zum 5. Mai 2025.
PMGC Capital ist der Ansicht, dass Alaunos unterbewertet ist und ein erhebliches Potenzial zur Wertschöpfung für Aktionäre bietet. Alaunos prüft derzeit strategische Alternativen, darunter Fusionen, Übernahmen, Vermögensverkäufe und strategische Partnerschaften. PMGC Capital plant, mit dem Management von Alaunos zusammenzuarbeiten, um strategische Chancen insbesondere in den Bereichen Fintech und Kryptowährungen zu erkunden.
- Acquisition of significant 5.09% stake shows confidence in Alaunos' potential
- Alaunos maintains a clean capital structure with prudent financial management
- Multiple strategic alternatives being explored including mergers, acquisitions, and partnerships
- Active engagement from PMGC Capital could accelerate value creation initiatives
- Potential shift from oncology focus to unrelated sectors (fintech/crypto) could be risky
- Company exploring strategic alternatives suggests possible challenges with current business model
- Relatively small float with only 1.64M shares outstanding may limit liquidity
Insights
PMGC Capital acquires 5.09% stake in Alaunos Therapeutics, signaling activist involvement in a company exploring strategic alternatives.
PMGC Capital, a subsidiary of PMGC Holdings (ELAB), has acquired a 5.09% stake in Alaunos Therapeutics (TCRT), triggering a Schedule 13D filing with the SEC. This is a significant development as it positions PMGC as an influential shareholder in a company actively exploring strategic alternatives.
The stake consists of 83,500 shares of Alaunos, which has only 1,639,521 shares outstanding as of May 5, 2025. This relatively small float makes PMGC's position particularly impactful, as they now have substantial voting power relative to the company's size.
What's particularly interesting is Alaunos' current strategic situation. The company is a clinical-stage oncology-focused cell therapy firm, but is explicitly exploring multiple strategic alternatives including acquisitions, mergers, reverse mergers, asset sales, and capital raises. PMGC's interest appears to be driving the company in a new direction, specifically mentioning potential opportunities in financial technology and cryptocurrency – sectors completely unrelated to Alaunos' current clinical focus.
This investment has all the hallmarks of a shell company play. PMGC is likely attracted to Alaunos' "clean capital structure" and Nasdaq listing, which could provide a vehicle for bringing private companies public through a reverse merger, circumventing the traditional IPO process. The transition from oncology to fintech/crypto would represent a complete business transformation, essentially using Alaunos as a publicly-traded shell.
For current Alaunos shareholders, this development may either represent an exit opportunity or a fundamental shift in investment thesis, as the company's direction could change dramatically under PMGC's influence.
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).
PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately
Alaunos Therapeutics, Inc. (“Alaunos Therapeutics” or “Alaunos”), headquartered in Houston, Texas, is a clinical-stage oncology-focused cell therapy company. Alaunos is currently exploring strategic alternatives, including but not limited to acquisitions, mergers, reverse mergers, sale of assets, strategic partnerships, capital raises, or other transactions.
PMGC Capital believes Alaunos is undervalued and has significant potential to create shareholder value. PMGC Capital intends to engage constructively with Alaunos’ management and board of directors to explore strategic opportunities, including potential mergers, acquisitions or partnerships in sectors such as financial technology and cryptocurrency.
We commend Alaunos Therapeutics for maintaining a clean capital structure and exercising prudent financial stewardship during challenging market conditions. PMGC Capital looks forward to collaborating with the Alaunos' leadership to pursue initiatives that align with its shared objective of enhancing long-term shareholder value.
About PMGC Capital LLC
A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Our mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital.
About PMGC Holdings Inc.
PMGC Holdings Inc. (“PMGC Holdings”) is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding potential strategic opportunities and the expected benefits thereof. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in the Company’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of PMGC Holdings’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
FAQ
What percentage stake did PMGC Capital acquire in Alaunos Therapeutics (TCRT)?
What strategic alternatives is Alaunos Therapeutics (TCRT) currently exploring?
What sectors does PMGC Capital want to explore for Alaunos Therapeutics' future opportunities?
How many outstanding shares does Alaunos Therapeutics (TCRT) have as of May 2025?
What is PMGC Capital's parent company and stock symbol?
